Tiziana Life Sciences Ltd. Common Shares (TLSA) Dividend History

Company News

• Tiziana Life Sciences to Present at the 37th Annual Roth Conference

  Tiziana Life Sciences, a biotechnology company, announced that its CEO will present at the 37th Annual ROTH Conference. The company's lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, has shown promising results in an open-label expanded access program and is currently being studied in a Phase 2a trial for non-active secondary progressive multiple sclerosis.

  GlobeNewswire Inc.
• Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

  Tiziana Life Sciences announced positive results from preclinical studies using its nasal anti-CD3 monoclonal antibody in treating traumatic spinal cord injury. The treatment demonstrated notable improvements in motor function, highlighting its potential as a transformative therapeutic approach.

  GlobeNewswire Inc.
• Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

  Tiziana Life Sciences, a biotechnology company, will participate in the BIO-Europe 2024 conference to discuss recent clinical progress, including positive data from its combination study involving Ozempic, a GLP-1 agonist. The company aims to engage with industry leaders, potential collaborators, and investors to accelerate the development of its therapeutic pipeline.

  GlobeNewswire Inc.
• Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

  Tiziana Life Sciences announced a $5 million registered direct offering, with an option for an additional $5 million. The company plans to use the proceeds to fund clinical trials for its lead candidate, intranasal foralumab, in multiple sclerosis and Alzheimer's disease.

  GlobeNewswire Inc.
• Tiziana Receives $3.4 Million in Non-Dilutive Funding

  NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here.

  GlobeNewswire Inc.